等待開盤 10-16 09:00:00
-0.960
-8.08%
Immutep Limited has received positive feedback from the FDA confirming 30mg of eftilagimod alfa (efti) as the optimal biological dose for its oncology pipeline and future Biological License Applications (BLA). The registrational TACTI-004 (KEYNOTE-F91) Phase III trial for first-line non-small cell lung cancer (NSCLC) is now opening clinical sites in the United States. This trial evaluates efti combined with MSD’s KEYTRUDA and chemotherapy for adv...
10-13 12:00
新股赚钱效应不断!“新能源领域超购王”挚达科技周涨逾192%,长风药业周涨近110%; 北大青鸟环宇周涨75.3%,旗下公司三方合作实现AR画质突破>>
10-10 18:13
本文来自格隆汇专栏:阿基米德Biotech BD预期已形成堰塞湖。 恒生生物科技指数(HSHKBIO)在节日期间上涨3.7%,重燃创新药二次行情的希望,但在节后...
10-10 08:16
10月9日,港股三大指数涨跌不一。截至收盘,恒生指数跌0.29%,国企指数涨0.07%,恒生科技指数跌0.66%。 分板块看,电力设备股、风电股、核电、绿电概念...
10-09 16:53
(来源:BBW咏竹坊) 创新药企业宜明昂科(1541.HK)周四宣布,拟配售2,420万股新H股,约占扩大后股本约5.61%,集资3.51亿港元...
10-09 12:15
Immutep’s TACTI-004 Phase III trial for eftilagimod alfa in advanced NSCLC has enrolled over 170 patients, surpassing the threshold for futility analysis. Over 100 sites across 24 countries are activated. The futility analysis is on track for Q1 2026. Previous studies showed promising efficacy of efti combined with KEYTRUDA, addressing high unmet need in NSCLC.
10-09 12:00
(来源:国医盛视) 一、医药核心观点 9.29-10.7 回顾与周专题: 十一期间(9.29-10.7)港股申万医药指数上涨8.33%...
10-08 18:54